v3.26.1
Summary of Significant Accounting Policies and Recent Accounting Standards (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2024
Dec. 31, 2025
Dec. 31, 2024
Aug. 31, 2024
Product Information [Line Items]            
Deposit money market       $ 10,000    
Restricted cash $ 700,000          
Cash and cash equivalents 3,324,000 $ 7,708,000 $ 9,521,000 4,088,000 $ 9,521,000  
Research and development expense $ 3,000 $ 19,000   $ 38,000 $ 7,166,000  
Stock options excluded from diluted loss per share 349,874 968,419   416,446,000 968,419,000  
Eos SENOLYTIXS Inc [Member]            
Product Information [Line Items]            
Cash and cash equivalents $ 14,934    
Research and development expense $ 449,183 $ 23,225 $ 8,970 $ 35,225    
Stock options excluded from diluted loss per share 848,694 666,344 137,815 683,990    
Letter of Credit [Member]            
Product Information [Line Items]            
Restricted cash     $ 1,421,000   $ 1,421,000 $ 1,400,000
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]            
Product Information [Line Items]            
Concentration risk percentage         100.00%